DnB Asset Management’s PTC Therapeutics PTCT Stock Holding History

DnB Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$356K	Hold	4,369	–	–	﹤0.01%	945
2026 Q1	$298K	Buy	+4,369	New	+$309K	﹤0.01%	983

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

DnB Asset Management's PTCT Position: Q2 2026 in Review

DnB Asset Management held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 4,369 shares worth $356K. The position accounts for ﹤0.01% of the portfolio, ranked #945.

DnB Asset Management first reported a position in PTCT in Q1 2026 and has held it in 2 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

DnB Asset Management held 4,369 shares of PTC Therapeutics worth $356K as of Q2 2026.
DnB Asset Management left its PTC Therapeutics share count unchanged in Q2 2026.
PTC Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #945 holding.
DnB Asset Management first reported a position in PTC Therapeutics in Q1 2026 and has held it in 2 quarters since.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.